Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R2-MT regimen in newly diagnosed primary CNS lymphoma
ChiCTR2500095350Phase 4Recruiting
- Sponsor
- Guiyang Second People's Hospital
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenalidomide, rituximab, methotrexate and temozolomide in Diffuse Large B-Cell Primary Central Nervous System Lymphoma, sponsored by Guiyang Second People's Hospital. Primary endpoints: Objective response rate and Event-free survival. Started Jan 2025; status: recruiting.
02
Drugs
lenalidomiderituximabmethotrexatetemozolomide
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System Lymphoma
Beyond the preview
Go deeper on ChiCTR2500095350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095350.